SPONSORED CONTENT

Dr Yukata Niihara felicitated by Minister of State, Arun Halder for developing FDA- approved drug ENDARI to fight SCD

December 16, 2022 23:45 IST | ANI Press Release
Tennis player James Blake
Dr Yukata Niihara was felicitated in an event held at the World Trade Center, Cuffe Parade by the Minister of State, Arun Halder

New Delhi [India], December 16 (ANI/SRV): Dr Yukata Niihara, e CEO and Chair of Emmaus life sciences Inc. USA, an internationally renowned doctor with over a dozen awards and citations, was felicitated in an event held at the World Trade Center, Cuffe Parade by the Minister of State, Arun Halder. This felicitation came as a recognition of Dr Yuktaka Niihara's work - the development of an FDA-approved drug ENDARI to fight the scrounge of Sickle cell syndrome worldwide. The event was hosted by Dr Aditi Govatrikar, a famous Bollywood personality, and Miss World.

Over 20 million people in India suffer from sickle cell disease (SCD) due to genetic reasons. Tribal communities, in particular, are affected at a disproportionately high percentage and suffer exorbitantly because of being underprivileged and lack of resources. To ameliorate their condition and save hundreds of lives, it is vitally necessary to introduce this medication in India.

Dr Niihara has tied up with an Indian Mumbai-based company, Akash Biomatrix Pvt. Ltd. represented by the undersigned to market and distribute this medicine in India at affordable prices. Emmaus Life sciences Inc of the USA is also seriously exploring setting up a manufacturing and Biotech research facility in India with an initial investment of over USD 300 million.

This story has been provided by SRV. ANI will not be responsible in any way for the content in this article. (ANI/SRV)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

 

Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .